Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Kaken Pharmaceutical Co's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Kaken Pharmaceutical Co's highest Yield on Cost was 5.95. The lowest was 2.30. And the median was 4.05.
KKPCF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.29 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Kaken Pharmaceutical Co (OTCPK:KKPCF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Kaken Pharmaceutical Co 5-Year Yield-on-Cost % Related Terms
KKPCF vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's 5-Year Yield-on-Cost % falls into.
Kaken Pharmaceutical Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Kaken Pharmaceutical Co (KKPCF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Kaken Pharmaceutical Co and its competitors. Over the past decade, Kaken Pharmaceutical Co's 5-Year Yield-on-Cost % has ranged from 2.30 to 5.95. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #112 out of 513 companies in the Drug Manufacturers industry, placing it in the top 21.8%.
Is Kaken Pharmaceutical Co's 5-Year Yield-on-Cost % too high?
Kaken Pharmaceutical Co's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 2.30 to a high of 5.95. Based on the distribution chart, Kaken Pharmaceutical Co ranks #112 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #112 out of 513 companies for 5-Year Yield-on-Cost %. This places Kaken Pharmaceutical Co in the top 22% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.29. Historically, Kaken Pharmaceutical Co's own 5-Year Yield-on-Cost % has ranged from 2.30 to 5.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Kaken Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Kaken Pharmaceutical Co (KKPCF) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is $25.42, compared to a current price of $26.00 — trading 2.3% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Kaken Pharmaceutical Co (KKPCF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (KKPCF) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of $26.00 is trading 2.3% above its estimated GF Value™ of $25.42.
Key valuation signals for KKPCF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $25.42 vs. price of $26.00 (2.3% above fair value)
No single metric tells the full story. See the KKPCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for KKPCF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KKPCF has been successfully added to your 
